What Happened?
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) fell 7% in the morning session after investors reacted to the company's weak full-year guidance ahead of its upcoming earnings report, alongside concerns over project delays highlighted by industry peer Danaher. The cautious outlook amplified bearish sentiment before Repligen's second-quarter results, expected on July 28. The guidance signaled expectations for slower growth and tougher near-term conditions. Adding to the pressure, life sciences company Danaher reported its second-quarter results, noting that customer-project timing weighed heavily on its bioprocessing business. Danaher revealed that over $100 million in bioprocessing revenue shifted into 2027 due to these delays, sending its shares down nearly 15%. This sector-wide weakness directly affected Repligen, which has a history of uneven profit trends and relies heavily on capital equipment orders vulnerable to similar customer project delays. The combination of Repligen's conservative outlook and broader bioprocessing challenges drove the stock lower.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Repligen? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Repligen’s shares are quite volatile and have had 16 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 12 months ago when the stock gained 7.8% on the news that the company reported strong second-quarter 2025 financial results and raised its full-year guidance. The life sciences company announced that its revenue climbed 15% year-over-year to $182 million, driven by growth across all its franchises and geographies. Profitability also saw a substantial increase, with net income rising to $14.87 million from $5.71 million in the same quarter last year. A key indicator of future performance, company orders, grew by over 20%. Buoyed by these strong results, Repligen lifted its full-year 2025 revenue forecast to a range of $715 million to $735 million.
Repligen is down 18.8% since the beginning of the year, and at $133.44 per share, it is trading 22.5% below its 52-week high of $172.26 from January 2026. Investors who bought $1,000 worth of Repligen’s shares 5 years ago would now be looking at only $655.38.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
